Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 759-770 , October 2009

177Lu- labeled MOv18 as compared to 131I- or 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts

  • Alberto Zacchetti

      Affiliations

    • Unit of Molecular Therapies, Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy
    • ,
  • Angela Coliva

      Affiliations

    • Department of Imaging and Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy
    • ,
  • Elena Luison

      Affiliations

    • Unit of Molecular Therapies, Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy
    • ,
  • Ettore Seregni

      Affiliations

    • Department of Imaging and Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy
    • ,
  • Emilio Bombardieri

      Affiliations

    • Department of Imaging and Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy
    • ,
  • Augusto Giussani

      Affiliations

    • Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
    • ,
  • Mariangela Figini

      Affiliations

    • Unit of Molecular Therapies, Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy
    • M.F. and S.C. contributed equally to this work.
    • ,
  • Silvana Canevari

      Affiliations

    • Unit of Molecular Therapies, Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +390223902567; fax: +390223903073.
    • M.F. and S.C. contributed equally to this work.

Received 31 March 2009 ,Revised 13 May 2009 ,Accepted 15 May 2009.

References 

  1. von GV, Daly B, Gibbons H, Hutchins J, Green A. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. Cancer. 2008;112:2221–2227
  2. Ayhan A, Gultekin M, Celik NY, Dursun P, Taskiran C, Aksan G, et al. Occult metastasis in early ovarian cancers: risk factors and associated prognosis. Am J Obstet Gynecol. 2007;196:81–86
  3. Epithelial ovarian cancer. In:  Berek JS,  Hacker NF editor. Practical gynecological oncology. Baltimore: Williams and Wilkins; 1994;p. 327
  4. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9:167–181
  5. Luborsky JL, Barua A, Shatavi SV, Kebede T, Abramowicz J, Rotmensch J. Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol. 2005;54:55–62
  6. Nicodemus CF, Berek JS. Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther. 2005;5:87–96
  7. Coliva A, Seregni E, Figini M, Zacchetti A, Fontanelli R, Raspagliesi F, et al. Nuclear medicine in the treatment of ovarian cancer. In:  Bombardieri E,  Buscombe JR,  Lucignani G,  Schober O editor. Advances in nuclear oncology: diagnosis and therapy. London: Informa Healthcare; 2007;p. 383–396
  8. Oei AL, Sweep FC, Thomas CM, Boerman OC, Massuger LF. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer. review Int J Oncol. 2008;32:1145–1157
  9. Koppe MJ, Postema EJ, Aarts F, Oyen WJ, Bleichrodt RP, Boerman OC. Antibody-guided radiation therapy of cancer. Cancer Metastasis Rev. 2005;24:539–567
  10. Knogler K, Grunberg J, Zimmermann K, Cohrs S, Honer M, Ametamey S, et al. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis. Clin Cancer Res. 2007;13:603–611
  11. Lewington V. Development of 131I-tositumomab. Semin Oncol. 2005;32:S50–S56
  12. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys. 1993;20:551–567
  13. Almqvist Y, Steffen AC, Tolmachev V, Divgi CR, Sundin A. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer. Nucl Med Biol. 2006;33:991–998
  14. Crippa F, Buraggi GL, Di Re E, Gasparini M, Seregni E, Canevari S, et al. Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. Eur J Cancer. 1991;27:724–729
  15. Crippa F, Bolis G, Seregni E, Gavoni N, Bombardieri E, Scarfone G, et al. Single dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 131I-MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer. 1995;31A:686–690
  16. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res. 1992;52:6708–6711
  17. Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;121:225–233
  18. Zhu D, Pauli BU. Generation of monoclonal antibodies directed against organ- specific endothelial cell surface determinants. J Histochem Cytochem. 1991;39:1137–1142
  19. Andersson H, Lindegren S, Back T, Jacobsson L, Leser G, Horvath G. Biokinetics of the monoclonal antibodies MOv 18, OV 185 and OV 197 labelled with 125I according to the m-MeATE method or the Iodogen method in nude mice with ovarian cancer xenografts. Acta Oncol. 1999;38:323–328
  20. Andersson H, Palm S, Lindegren S, Back T, Jacobsson L, Leser G, et al. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. Anticancer Res. 2001;21:409–412
  21. Gadina M, Canevari S, Ripamonti M, Mariani M, Colnaghi MI. Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18. Nucl Med Biol. 1991;18:403–408
  22. Coliva A, Zacchetti A, Luison E, Tomassetti A, Bongarzone I, Seregni E, et al. . 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother. 2005;54:1200–1213
  23. Figini M, Martin F, Ferri R, Luison E, Ripamonti E, Zacchetti A, et al. Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor. Cancer Immunol Immunother. 2009;58:531–546
  24. Committee on Cancer Research (UKCCCR), United Kingdom . Guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer. 1998;77:1–10
  25. 2000 Report of the AVMA panel on euthanasia. J Am Vet Med Assoc. 2001;218:669–696
  26. International Union of Pure and Applied Chemistry CoCT . The Gold Book. 2nd ed.. Oxford: Blackwell Scientific Publications; 1997;
  27. Foltz CJ, Ullman-Cullere M. Guidelines for assessing the health and condition of mice. Lab Animal. 1999;28:28–32
  28. Behr TM, Sgouros G, Vougiokas V, Memtsoudis S, Gratz S, Schmidberger H, et al. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer. 1998;76:738–748
  29. Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, et al. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. J Nucl Med. 2001;42:967–974
  30. Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res. 2005;11:7053s–7063s
  31. Beck R, Seidl C, Pfost B, Morgenstern A, Bruchertseifer F, Baum H, et al. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice. Cancer Sci. 2007;98:1215–1222
  32. Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer. 1997;80:2591–2610
  33. Casalini P, Luison E, Menard S, Colnaghi MI, Paganelli G, Canevari S. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med. 1997;38:1378–1381
  34. Mantovani LT, Miotti S, Menard S, Canevari S, Raspagliesi F, Bottini C, et al. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer. 1994;30A:363–369
  35. Casalini P, Mezzanzanica D, Canevari S, Della Torre G, Miotti S, Colnaghi MI, et al. Use of combination of monoclonal antibodies directed against three distinct epitopes of a tumor-associated antigen: analysis of cell binding and internalization. Int J Cancer. 1991;48:284–290
  36. Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med. 2004;45:327–337
  37. Siegel JA. Quantitative Bremsstrahlung SPECT imaging: attenuation-corrected activity determination. J Nucl Med. 1994;35:1213–1216
  38. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995;36:1902–1909
  39. Coney LR, Mezzanzanica D, Sanborn D, Casalini P, Colnaghi MI, Zurawski VR. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res. 1994;54:2448–2455

PII: S0969-8051(09)00129-2

doi: 10.1016/j.nucmedbio.2009.05.004

Nuclear Medicine and Biology
Volume 36, Issue 7 , Pages 759-770 , October 2009

Article Tools

* Image Usage & Resolution